Neurology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Correspondence:
Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when Correspondence are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Good, J. L.
Right arrow Articles by Koski, C. L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Good, J. L.
Right arrow Articles by Koski, C. L.
NEUROLOGY 1998;51:1735-1738
© 1998 American Academy of Neurology

Pulse cyclophosphamide therapy in chronic inflammatory demyelinating polyneuropathy

Janine Louisa Good, MD, Mahan Chehrenama, DO, Richard Frederick Mayer, MD and Carol Lee Koski, MD

From the University of Maryland School of Medicine, Deparment of Neurology, Baltimore, MD.

Address correspondence and reprint requests to Dr. Janine L. Good, University of Maryland School of Medicine, Department of Neurology, 22 S. Greene Street, Baltimore, MD 21201.

Fifteen patients with chronic inflammatory demyelinating neuropathy (CIDP) were treated with pulse intravenous cyclophosphamide (IVCY) monthly for up to 6 months. Eleven patients reached a complete remission; only one patient worsened. Complications included nausea, vomiting, anemia, and hair loss. This case series suggests that monthly IVCY is beneficial in the treatment of CIDP and warrants a controlled study.


Received December 26, 1997. Accepted in final form July 23, 1998.




This article has been cited by other articles:


Home page
Therapeutic Advances in Neurological DisordersHome page
H. C. Lehmann, G. Meyer zu Horste, B. C. Kieseier, and H.-P. Hartung
Review: Pathogenesis and treatment of immune-mediated neuropathies
Therapeutic Advances in Neurological Disorders, July 1, 2009; 2(4): 261 - 281.
[Abstract] [PDF]


Home page
J. Neurol. Neurosurg. PsychiatryHome page
D Fialho, Y-C Chan, D C Allen, M M Reilly, and R A C Hughes
Treatment of chronic inflammatory demyelinating polyradiculoneuropathy with methotrexate
J. Neurol. Neurosurg. Psychiatry, April 1, 2006; 77(4): 544 - 547.
[Abstract] [Full Text] [PDF]


Home page
PNHome page
J. R Overell and H. J Willison
Chronic inflammatory demyelinating polyradiculoneuropathy: classification and treatment options
Practical Neurology, April 1, 2006; 6(2): 102 - 110.
[Full Text] [PDF]


Home page
J. Neurol. Neurosurg. PsychiatryHome page
M Odaka, M Tatsumoto, K Susuki, K Hirata, and N Yuki
Intractable chronic inflammatory demyelinating polyneuropathy treated successfully with ciclosporin
J. Neurol. Neurosurg. Psychiatry, August 1, 2005; 76(8): 1115 - 1120.
[Abstract] [Full Text] [PDF]


Home page
NEJMHome page
H. Koller, B. C. Kieseier, S. Jander, and H.-P. Hartung
Chronic Inflammatory Demyelinating Polyneuropathy
N. Engl. J. Med., March 31, 2005; 352(13): 1343 - 1356.
[Full Text] [PDF]


Home page
NEJMHome page
H. W. Sander and E. T. Hedley-Whyte
Case 6-2003 - A Nine-Year-Old Girl with Progressive Weakness and Areflexia
N. Engl. J. Med., February 20, 2003; 348(8): 735 - 743.
[Full Text] [PDF]


Home page
NeurologyHome page
C. L. Koski
Therapy of CIDP and related immune-mediated neuropathies
Neurology, December 24, 2002; 59(90126): S22 - 27.
[Abstract] [Full Text]


Home page
Arch NeurolHome page
S. J. Pittock, D. Meldrum, and O. Hardiman
The "Spray Can" Sign: Validation of a Clinical Observation in Chronic Inflammatory Demyelinating Polyneuropathy
Arch Neurol, October 1, 2002; 59(10): 1637 - 1640.
[Abstract] [Full Text] [PDF]


Home page
NeurologyHome page
T.H. Brannagan III, A. Pradhan, T. Heiman-Patterson, A.C. Winkelman, M.J. Styler, D.L. Topolsky, P.A. Crilley, R.J. Schwartzman, I. Brodsky, and D.E. Gladstone
High-dose cyclophosphamide without stem-cell rescue for refractory CIDP
Neurology, June 25, 2002; 58(12): 1856 - 1858.
[Abstract] [Full Text] [PDF]


Home page
Mult SclerHome page
H L Weiner and J A Cohen
Treatment of multiple sclerosis with cyclophosphamide: critical review of clinical and immunologic effects
Multiple Sclerosis, April 1, 2002; 8(2): 142 - 154.
[Abstract] [PDF]


Home page
J. Immunol.Home page
Z. Illes, T. Kondo, J. Newcombe, N. Oka, T. Tabira, and T. Yamamura
Differential Expression of NK T Cell V{alpha}24J{alpha}Q Invariant TCR Chain in the Lesions of Multiple Sclerosis and Chronic Inflammatory Demyelinating Polyneuropathy
J. Immunol., April 15, 2000; 164(8): 4375 - 4381.
[Abstract] [Full Text] [PDF]


Home page
NeurologyHome page
K. Ikeda, Y. Iwasaki, N. Hatanaka, M. Kinoshita, N. Wakata, J. L. Good, C. L. Koski, R. F. Mayer, and M. Chehrenama
Pulse cyclophosphamide therapy in CIDP
Neurology, September 1, 1999; 53(4): 894 - 894.
[Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1998 by AAN Enterprises, Inc.